

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 084 710 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

21.03.2001 Bulletin 2001/12

(51) Int. Cl.⁷: **A61K 45/00**, **A61K 31/435**,
A61K 31/52, **C07D 471/04**,
C07D 473/04

(21) Application number: 99922530.3

(22) Date of filing: 28.05.1999

(86) International application number:
PCT/JP99/02811

(87) International publication number:
WO 99/62553 (09.12.1999 Gazette 1999/49)

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

(30) Priority: 01.06.1998 JP 15122498

09.11.1998 JP 31779598

(71) Applicant:

FUJISAWA PHARMACEUTICAL CO., LTD.
Osaka-shi Osaka 541-8514 (JP)

(72) Inventors:

• KANEKO, Satoru
Ichikawa-shi, Chiba 272-0015 (JP)

• NOMURA, Kazuhiko

Takatsuki-shi, Osaka 569-0815 (JP)

• KOHNO, Yutaka

Ibaraki-shi, Osaka 567-0828 (JP)

• KODAMA, Hiroshi

Tsukuba-shi, Ibaraki 305-0863 (JP)

• KAJIHO, Tokuaki

Kobe-shi, Hyogo 651-1121 (JP)

(74) Representative:

Gille Hrabal Struck Neidlein Prop Roos
Patentanwälte,
Brucknerstrasse 20
40593 Düsseldorf (DE)

(54) **REMEDIES FOR MALE STERILITY**

(57) Efficacious remedies for male sterility which
are in the form of preparations containing as the active
ingredient an adenosine A₁ antagonist.

EP 1 084 710 A1

Description

TECHNICAL FIELD

- 5 [0001] The present invention relates to a therapeutic agent for male sterility which comprises an adenosine A₁ antagonist or a salt thereof as an active ingredient and so is useful in the pharmaceutical field.

BACKGROUND ART

- 10 [0002] The infertile male population has recently been on the steady increase and, alongside endocrine disruptors in environment inclusive of dioxins, the so-called male sterility is a matter of serious concern to the society at large.
 [0003] However, no satisfactory remedy has been established for the therapy of this disease as yet and the assisted reproductive technology such as intracytoplasmic (intraoosomal) sperm injection (ICSI) is an exclusive choice available today. ICSI is a laudably effective fertilizing method but is defective in terms of safety in that the genetic check of the
 15 sperm cannot be made. Furthermore, because the selection of fertile sperm is entrusted to the human hand, the method has ethically a negative aspect and, in addition, since the cost of the procedure is exorbitant and not covered by an insurance, many patients have to abandon the idea to receive the treatment.
 [0004] Therefore, there is a keen demand from the medical scene for a fertilizing technology which would be less costly than ICSI and more natural in that the sperm would be encouraged to enter the ova by its own efforts.
 20 [0005] The acrosomal reaction is indispensable to the penetration of sperm through the pellucid zone of the ovum and it is considered to be very efficacious to promote the induction of sperm acrosomal reaction of sperm for the therapy of male sterility.
 [0006] It is generally considered that the induction of sperm acrosomal reaction in infertile men can be promoted by inhibiting the sperm phosphodiesterase and, aiming at this inhibition, such drugs as caffeine and pentoxifylline
 25 have been used on an empirical basis.
 [0007] However, the promotion of induction of sperm acrosomal reaction with such drugs has not been fruitful enough.
 [0008] In the field of therapy for male sterility today, there exists a demand for an effective acrosomal reaction induction promoter and the present invention has for its object to solve the above problem.

DISCLOSURE OF INVENTION

- [0009] The present inventor obtained a novel finding quite dissimilar to the earlier notion, namely "the induction of acrosomal reaction can be promoted by inhibiting the binding of adenosine to the adenosine A₁ receptor of the sperm",
 35 has accomplished the present invention. The present invention, therefore, provides a therapeutic composition comprising an adenosine A₁ receptor antagonist or a salt thereof as an active ingredient to thereby solve the above-mentioned problem.
 [0010] To demonstrate that the induction of acrosomal reaction in infertile men can be promoted by inhibiting the binding of adenosine to the adenosine A₁ receptor of the sperm, the influence of adenosine A₁ antagonists on the
 40 human sperm acrosomal reaction was investigated using the following test compounds which are well-known specific adenosine A₁ antagonists.

Test compounds

- 45 [0011]
 (A) 3-[2-(3-Carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine
 (B) (2R)-1-[3-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(carboxymethyl)piperidine (trans isomer)
 50 (C) 3-[2-(2-Carboxymethyl-1-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine

[Test for evaluation of the promoting effect on the induction of sperm acrosomal reaction]

1. Method

- 55 [0012] Percoll for sperm washing was isotonized and adjusted to 90% with 20 mM Hepes buffered Hanks solution (pH 7.4; supplemented with 1.0 mg/ml BSA). The ejaculated human seminal fluid was allowed to liquefy at room temperature, diluted 2-fold with Hanks solution, and layered on 6.0 ml Percoll. In the Percoll layer, a glass capillary had been inserted in advance. The system was centrifuged at 1000 × g for 30 minutes to precipitate motile sperm. The pre-

cipitated sperm was aspirated through the capillary and recovered. The sperm was resuspended in Hanks solution at a final concentration of about $50 \times 10^6/\text{ml}$ and cultured at 37°C .

[0013] The human sperm acrosomal reaction was monitored by a fluorescence staining technique using FITC-concanavalin A.

5 [0014] As the acrosomal cap splits off on acrosomal reaction, the membrane protein, rich in the high-mannose sugar chain on the acrosomal tunica intima becomes exposed. Therefore, the sperm showing a yellow fluorescence in the anterior half of the head was regarded as acrosomal reaction-induced sperm.

[0015] Compound A was added to the sperm suspension at a final concentration of 10^{-6} or 10^{-7} M. Observation was made in the group supplemented with 1 I.U./ml of adenosine deaminase and the non-enzyme-addition group.

10 [0016] Compounds B and C were respectively added to the sperm suspension at a final concentration of 10^{-7} M. Observation was made in the groups supplemented with 1 I.U./ml of adenosine deaminase.

2. Results

15 [0017] The test results are shown in the following tables. Each figure denotes the acrosomal reaction induction rate (%) (the mean \pm S.E. of 3 observations in Table 1; the mean \pm S.E. of 5 observations in Tables 2 and 3). In Table 1, the figure in the top row represents the result obtained in the absence of adenosine deaminase and the figures in the bottom row represent the results in the presence of adenosine deaminase.

20 Table 1

Incubation time	Compound A, concentration (M)		
	0	10^{-6}	10^{-7}
0	6.54 \pm 1.87	-	-
3	27.1 \pm 2.35	43.7 \pm 2.77	47.1 \pm 2.37
	32.7 \pm 2.45	63.6 \pm 1.84	64.1 \pm 1.73

35 Table 2

Incubation time	Compound B, concentration (M)	
	0	10^{-7}
3	30.98 \pm 1.17	41.26 \pm 2.18

45 Table 3

Incubation time	Compound C, concentration (M)	
	0	10^{-7}
3	34.20 \pm 2.93	48.86 \pm 2.57

50 [0018] The finding that the induction of acrosomal reaction was promoted in the presence of adenosine deaminase suggests that the induction of acrosomal reaction is inhibited in the presence of adenosine. Furthermore, the finding that the induction of acrosomal reaction was promoted by Compounds A, B and C, which are specific adenosine A_1 antagonists, suggests that the induction of acrosomal reaction is inhibited by the binding of adenosine to the adenosine A_1 receptor.

[0019] It has, thus, been proven that adenosine A_1 antagonists promote the induction of acrosomal reaction.

[0020] The present invention is carried into practice by submitting an adenosine A₁ antagonist or a salt thereof, either as it is or in the form of a pharmaceutical composition containing an adenosine A₁ antagonist or a salt thereof as an active ingredient, to a patient with male sterility.

[0021] The term "adenosine A₁ antagonist" as used in this specification means a substance that opposes the action of adenosine on adenosine A₁ receptors and includes all substances falling within the category of "adenosine A₁ antagonist" as established in the art. A large number of compounds are already known as adenosine A₁ antagonists and even novel compounds that is regarded as adenosine A₁ antagonists should also be included in the category of adenosine A₁ antagonists in the context of the present invention.

[0022] The existence as well as the intensity of action of "adenosine A₁ antagonist" can be evaluated typically by the following method. The intensity of adenosine A₁ antagonist action as referred to in the claims also means a quantity found by the following evaluation method. "Test for adenosine A₁ antagonist action"

(1) Preparation of a rat brain homogenate

[0023] The rat brain homogenate is used in the adenosine A₁ receptor binding assay. The brains isolated from male SD rats weighing about 200~300 g are homogenized in 20 parts (w/v) of 50 mM Tris-HCl buffer (pH 7.4, 25°C) using Polytron homogenizer (Kinematica GmbH). The homogenate is centrifuged (4°C) at 41000 × g for 30 minutes. The resulting pellet is resuspended in 20 parts of buffer solution (50 mM, pH 7.4). To this is added adenosine deaminase (2 I.U./ml), and the mixture is incubated at 37°C for 30 minutes to remove the endogenous adenosine. This brain homogenate is recentrifuged and the resulting pellet is stored frozen at -70°C until used in the binding assay.

(2) The receptor binding assay using [³H]-N⁶-cyclohexyladenosine (³H-CHA) as a radioligand


[0024] The assay is performed in a system containing 1 nM ³H-CHA with a specific activity of 25 Ci/mmol and giving a final volume of 1 ml. Non-specific binding is determined in the presence of CHA (10 μM).

[0025] The reaction is started by adding the brain homogenate mentioned above at a final protein concentration of 200~300 μg/ml and the reaction mixture is incubated at 23°C for 3 hours. After this incubation, the bound radioactivity is isolated by filtration under vacuum through a Whatman GF/B glass fiber filter and the unbound radioactivity is washed off with 5 ml of ice-cooled buffer solution twice. The filter for each sample is placed in a glass vial, to which Aquasol II (manufactured by NEN Research Products) (10 ml) is added. After at least 12 hours of standing, the radioactivity is measured by the standard liquid scintillation spectroscopy.

[0026] In carrying the present invention into practice, it is advisable to use a specific adenosine A₁ antagonist having sufficiently high adenosine A₁ antagonist activity. For example, a compound giving an IC₅₀ value of not more than 100 μM, preferably not more than 50 μM, more preferably not more than 10 μM, particularly not more than 1 μM, in the above assay can be used with advantage. (Any one skilled in the art should interpret the above values with experimental errors and other variables taken into consideration). Thus, these values should be considered to be rules of thumb and rather one skilled in the art can judiciously select an adenosine A₁ antagonist suitable for the present invention by carrying out the above "Test for evaluation of the promoting effect on the induction of acrosomal reaction" and "Test for adenosine A₁ antagonist action".


[0027] In the above sense, a compound additionally possessed of a pharmacologic action other than adenosine A₁ antagonist action can likewise be used.

[0028] Structurally, pyrazolopyridine compounds of the following general formula (I) and their salts can be mentioned as typical examples of the adenosine A₁ antagonist.



[wherein R¹ is a lower alkyl, aryl which may have one or more suitable substituent(s), or a heterocyclic group,

R² is a group of the formula:



(wherein R⁴ is protected amino or hydroxy and R⁵ is hydrogen or lower alkyl);

cyano;

a group of the formula:



(wherein R⁶ is an acyl group and A is a lower aliphatic hydrocarbon group which may have one or more suitable substituent(s));

amidated carboxy;

unsaturated heterocyclic group which may have one or more suitable substituent(s);

amino; or

protected amino, and

R³ is hydrogen, lower alkyl, lower alkoxy, or halogen]

[0029] As the above pyrazolopyridine compound (I), there can be mentioned the known compounds described in, *inter alia*, Japanese laid-open (Kokai Tokkyo Koho) No. S64-45385, H2-243689, H4-253978, and H5-112566, and WO95/18128.

[0030] Suitable salts of the pyrazolopyridine compound (I) are pharmaceutically acceptable salts of the conventional kinds, for example metal salts such as alkali metal salts, (e.g. sodium salt, potassium salt, etc., and alkaline earth metal salts, e.g. calcium salt, magnesium salt, etc.), ammonium salts, organic base salts, such as trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc., organic acid salts, such as acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc., inorganic acid salts, such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, etc., and salts with amino acids such as arginine, aspartic acid, glutamic acid and so on.

[0031] Suitable examples and particulars of various terms defining the above pyrazolopyridine compound (I) are explained hereinbelow in detail.

[0032] The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.

[0033] The term "higher" is intended to mean 7 to 20 carbon atoms, unless otherwise indicated.

[0034] Suitable "lower aliphatic hydrocarbon group" may include the following lower alkyl, lower alkenyl and lower alkynyl groups.

[0035] Suitable "lower alkyl" may include straight or branched ones such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, and among these, the preferred one may be (C₁-C₄)alkyl and the more preferred one may be methyl, ethyl, propyl and isopropyl.

[0036] Suitable "lower alkenyl" may include straight or branched ones such as vinyl, 1-methylvinyl, 2-methylvinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-methyl-1-propenyl, 1,3-butadienyl, 1-pentenyl, 4-pentenyl, 1-hexenyl, 1,4-hexadienyl, 5-hexenyl or the like, and among these, the preferred one may be (C₂-C₄)alkenyl and the more preferred one may be vinyl, 1-methylvinyl, 2-methylvinyl and 1,3-butadienyl.

[0037] Suitable "lower alkynyl" may include straight or branched ones such as ethynyl, 1-propynyl, 1-methylethynyl, 2-butylnyl, 2-methyl-3-butylnyl, 2-pentylnyl, 1-hexynyl or the like, and among these, the preferred one may be (C₂-C₄)alkynyl and the more preferred one may be ethynyl.

[0038] The "lower aliphatic hydrocarbon group" mentioned above may have one or more, preferably 1 to 3, suitable substituent(s) such as halogen, (e.g. chloro, bromo, fluoro and iodo).

[0039] Suitable "protected amino group" may include amino substituted with the conventional amino-protective groups, such as lower alkylamino, (e.g. methylamino, ethylamino, propylamino, butylamino, tert-butylamino, pentylamino, hexylamino, etc.), di(lower)alkylamino, (e.g. dimethylamino, diethylamino, N-ethylpropylamino, dibutylamino, N-(tert-butyl)pentylamino, dihexylamino, etc.), and the acylamino groups mentioned below.

[0040] Suitable "acylamino" may include ureido; lower alkanoylamino, (e.g. formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pivaloylamino, hexanoylamino, etc.); lower alkoxy-carbonylamino, (e.g. methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, tert-butoxycarbonylamino, pentyloxycarbonylamino, hexyloxycarbonylamino, etc.); lower alkoxy-carbonyl(lower)alkanoylamino, (e.g. methoxycarbonylacet-
 5 carbonylacetamino, 2-(propoxycarbonyl)propionylamino, 4-(tert-butoxycarbonyl)butyrylamino, 2-(butoxycarbonyl-methyl)propionylamino, 2-methyl-2-(pentyloxycarbonylmethyl)-propionylamino, 6-hexyloxycarbonylhexanoylamino, etc.); and lower alkanesulfonylamino, (e.g. methanesulfonylamino, ethanesulfonylamino, propanesulfonylamino, butanesulfonylamino, tert-butanesulfonylamino, pentanesulfonylamino, hexanesulfonylamino, etc).

[0041] The "lower alkanoylamino" mentioned above may have suitable substituent(s) such as di(lower)alkylamino groups, (e.g. dimethylamino, N-methyl-N-ethylamino, dipropylamino, di-tert-butylamino, N-pentyl-N-hexylamino, etc.); and cyclic amino groups which may have suitable substituents, (e.g. piperidino, etc.). Suitable examples of the said "lower alkanoylamino groups having suitable substituent(s)" may include lower alkanoylamino having di(lower)alkylamino, such as dimethylaminocarbonylamino, 2-dimethylaminoacetylamino, 2-(N-methyl-N-ethyl-
 15 aminopropionylamino, 2-dimethylaminopropionylamino, 3-dipropylaminobutyrylamino, 2-(di-tert-butylamino)-2-methylpropionylamino, 2-dimethylaminomethyl-2-methylpropionylamino, 6-(N-pentyl-N-hexylamino)-hexanoylamino or the like; and lower alkanoylamino having cyclic amino groups optionally having lower alkyl, such as piperidinocarbonylamino, 2-piperidinoacetylamino, 2-(2-methylpiperidino)acetylamino, 2-(2-ethylpiperidino)acetylamino, 2-piperidinopropionylamino, 3-(2-ethylpiperidino)butyrylamino, 2-(4-ethylpiperidino)-2-methylpropionylamino, 2-piperidinomethyl-2-methylpropionylamino, 6-(3-propylpiperidino)-hexanoylamino or the like.

[0042] In aforesaid "acylamino", the preferred one may be ureido, (C₁-C₄)alkanoylamino, (C₁-C₄)alkoxy-carbonyl(C₁-C₄)alkanoylamino, di(C₁-C₄)alkylamino(C₁-C₄)alkanoylamino, (C₁-C₄)alkylpiperidino(C₁-C₄)alkanoylamino, (C₁-C₄)alkoxy-carbonylamino, (C₁-C₄)alkanesulfonylamino, (C₁-C₄)alkylamino and di(C₁-C₄)alkylamino, in which the more preferred one may be ureido, acetylamino, 2-(ethoxycarbonyl)acetylamino, 2-dimethylaminoacetylamino, 2-(2-ethylpiperidino)acetylamino, methoxycarbonylamino, methanesulfonylamino, methylamino and dimethylamino.

[0043] Suitable "acyl" may include lower alkanoyl such as formyl, acetyl, propionyl, butyryl, isobutyryl, pivaloyl, hexanoyl or the like; carboxy; and protected carboxy, and so on.

[0044] Suitable example of aforesaid "protected carboxy" may include esterified carboxy, the suitable example of which is lower alkoxy-carbonyl, (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, tert-butoxy-carbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.), which may have nitrogen-containing heterocyclic group; and
 30 amidated carboxy, the suitable examples of which are

N-(lower)alkylcarbamoyl such as N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N-pentylcarbamoyl, N-hexylcarbamoyl or the like;

N-(higher)alkylcarbamoyl such as N-heptylcarbamoyl, N-(2-methylheptyl)carbamoyl, N-nonylcarbamoyl, N-decan-
 35 ylcarbamoyl, N-tricyclo[3.3.1.1^{3,7}]decanylcarbamoyl, N-undecanylcarbamoyl, N-(bicyclo[4.3.2]undecanyl)carbamoyl, N-dodecanylcarbamoyl, N-tridecanylcarbamoyl, N-tetradecanylcarbamoyl, N-pentadecanylcarbamoyl, N-hexadecanylcarbamoyl, N-heptadecanylcarbamoyl, N-octadecanylcarbamoyl, N-nonadecanylcarbamoyl, N-icosan-ylcarbamoyl or the like;

N,N-di(lower)alkylcarbamoyl such as N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-di(tert-butyl)carbamoyl, N-pentyl-N-hexylcarbamoyl or the like;

N-(lower)alkyl-N-ar(lower)alkylcarbamoyl such as N-methyl-N-benzylcarbamoyl or the like;

a group of the formula: -CO-R_N

(wherein R_N is nitrogen-containing heterocyclic group optionally having one or more suitable substituent(s); this nitrogen-containing heterocyclic group R_N may contain another hetero atom(s) such as N, O and/or S in its ring).
 45

[0045] Suitable "nitrogen-containing heterocyclic group" may include saturated or unsaturated, monocyclic or poly-cyclic heterocyclic group such as unsaturated 3 to 8-membered (more preferably, 5 to 7-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, azepinyl (e.g. 1H-azepinyl, etc.), pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-
 50 1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), and tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.);

saturated 3 to 8-membered (more preferably 5 to 7-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, perhydroazepinyl (e.g. perhydro-1H-azepinyl, etc.), pyrrolidinyl, imidazolidinyl, piperidino and piperazinyl;

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl or the like;

saturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, 7-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.2]nonanyl or the like;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, and oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) or the like;

saturated 3 to 8-membered (more preferably, 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, or the like;

unsaturated fused heterocyclic groups containing 1~2 oxygen atoms and 1~3 nitrogen atoms, such as benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably, 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl (e.g. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl or the like;

saturated 3 to 8-membered (more preferably, 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl or the like;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl or the like.

[0046] Among these groups, the preferred one may include saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), saturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), and saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s).

[0047] These nitrogen-containing heterocyclic groups may each have one or more suitable substituent(s) such as lower alkyl as mentioned above; hydroxy(lower)alkyl (e.g. hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxybutyl, 1-methyl-1-hydroxymethylethyl, 4-hydroxypentyl, 3-hydroxyhexyl, etc.); lower alkoxy(lower)alkyl (e.g. methoxymethyl, 2-methoxyethyl, 1-ethoxyethyl, 3-propoxypropyl, 2-(tert-butoxy)butyl, 5-pentyloxypropyl, 3-hexyloxyhexyl, etc.); acyloxy(lower)alkyl such as lower alkanoyloxy(lower)alkyl (e.g. acetoxymethyl, 1-acetoxyethyl, 2-acetoxyethyl, 2-propionyloxyethyl, 3-propionyloxypropyl, 2-butyryloxybutyl, 4-pivaloyloxypropyl, 6-hexanoyloxyhexyl, etc.); protected carboxy such as said lower alkoxycarbonyloxy; carboxy; acyl(lower)alkyl such as lower alkanoyl(lower)alkyl (e.g. formylmethyl, 1-formylethyl, 2-acetyethyl, 2-formylpropyl, 3-propionylpropyl, 4-formylbutyl, 2-butyrylbutyl, 1-formylmethylethyl, 3-formylpentyl, 1-isobutyrylpentyl, 4-pivaloylpentyl, 2-formylhexyl, 6-hexanoylhexyl, etc.), carboxy(lower)alkyl (e.g. carboxymethyl, 1-carboxyethyl, 2-carboxypropyl, 1-carboxymethylethyl, 4-carboxybutyl, 3-carboxypentyl, 2-carboxyhexyl, etc.), protected carboxy(lower)alkyl [preferably, esterified carboxy(lower)alkyl, more preferably lower alkoxycarbonyl(lower)alkyl such as methoxycarbonylmethyl, 2-methoxycarbonylethyl, 1-ethoxycarbonylethyl, 2-propoxycarbonylpropyl, 1-methoxycarbonylmethylethyl, 4-1-butoxycarbonylbutyl, 3-pentyloxy carbonylpentyl, 2-hexyloxy carbonylhexyl or the like; and amidated carboxy(lower)alkyl, more preferably carbamoyl(lower)alkyl, N-(lower)alkylcarbamoyl(lower)alkyl (e.g. N-ethylcarbamoylmethyl, etc.) and N,N-di(lower)alkylcarbamoyl(lower)alkyl (e.g. N,N-diethylcarbamoylmethyl, etc.)] or the like.

[0048] Among said "nitrogen-containing heterocyclic groups which may have one or more suitable substituent(s)", the preferred one may include piperidino optionally having 1 to 4 suitable substituent(s) selected from a group consisting of (C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkoxy(C₁-C₄)alkyl, (C₁-C₄)alkanoyloxy(C₁-C₄)alkyl, (C₁-C₄)alkoxycarbonyl, carboxy, (C₁-C₄)alkanoyl(C₁-C₄)alkyl, carboxy(C₁-C₄)alkyl, (C₁-C₄)alkoxycarbonyl(C₁-C₄)alkyl, carbamoyl(C₁-C₄)alkyl, N-(C₁-C₄)alkylcarbamoyl(C₁-C₄)alkyl and N,N-di(C₁-C₄)alkylcarbamoyl(C₁-C₄)alkyl, such as piperidino, 2-methylpiperidino, 2-ethylpiperidino, 3-ethylpiperidino, 4-ethylpiperidino, 2-propylpiperidino, 4-isopropylpiperidino, 2-butylpiperidino, 3-(tert-butyl)piperidino, 2,2,6,6-tetramethylpiperidino, 2,2-dimethyl-6,6-diethylpiperidino, 2-hydroxymethylpiperidino, 3-hydroxymethylpiperidino, 2-(1-hydroxyethyl)piperidino, 2-(2-hydroxyethyl)piperidino, 3-(2-hydroxyethyl)piperidino, 4-(2-hydroxyethyl)piperidino, 2-(3-hydroxypropyl)piperidino, 3-(2-hydroxybutyl)piperidino, 2-(1-methyl-1-hydroxymethylethyl)piperidino, 2-methoxymethylpiperidino, 2-(2-methoxyethyl)piperidino, 2-(1-ethoxyethyl)piperidino, 3-(3-propoxypropyl)piperidino, 4-(2-(tert-butoxy)butyl)piperidino, 2-acetoxymethylpiperidino, 3-(1-acetoxyethyl)piperidino, 2-(2-acetoxyethyl)piperidino, 3-(2-propionyloxyethyl)piperidino, 4-(3-propionyloxypropyl)piperidino, 2-(2-butyryloxybutyl)piperidino, 2-methoxycarbonylpiperidino, 2-ethoxycarbonylpiperidino, 2-propoxycarbonylpiperidino, 3-butoxycarbonylpiperidino, 4-(tert-butoxycarbonyl)piperidino, 2-carboxypiperidino, 3-carboxypiperidino, 4-carboxypiperidino, 2-(2-hydroxyethyl)-3-methylpiperidino, 2-(2-hydroxyethyl)-4-carboxypiperidino, 2-formylmethylpiperidino, 2-(1-formylethyl)piperidino, 3-(2-acetyethyl)piperidino, 4-(2-formylpropyl)piperidino, 2-(3-propionylpropyl)piperidino, 2-(4-formylbutyl)piperidino, 3-(2-butyrylbutyl)piperidino, 2-{1-(formylmethyl)ethyl}piperidino, 2-carboxymethylpiperidino, 2-(1-carboxyethyl)piperidino, 3-(2-carboxypropyl)piperidino, 4-{1-(carboxymethyl)ethyl}piperidino, 2-(4-carboxybutyl)piperidino, 2-methoxycarbonylmethylpiperidino, 2-(2-methoxycarbonylethyl)piperidino, 3-(1-ethoxycarbonylethyl)piperidino, 4-(2-propoxycarbonylpropyl)piperidino, 2-{1-(methoxycarbonylmethyl)ethyl}piperidino, 2-(4-1-butoxycarbonylbutyl)piperidino or the like;

pyrrolidin-1-yl optionally having (C₁-C₄)alkoxy(C₁-C₄)alkyl, such as pyrrolidin-1-yl, 2-methoxymethylpyrrolidin-1-yl, 2-(2-methoxyethyl)pyrrolidin-1-yl, 2-(1-ethoxyethyl)pyrrolidin-1-yl, 3-(3-propoxypropyl)pyrrolidin-1-yl, 3-(2-(tert-

butoxy)butyl)pyrrolidin-1-yl or the like;

perhydroazepin-1-yl, such as perhydro-1H-azepin-1-yl or the like;

piperazin-1-yl optionally having (C₁-C₄)alkyl, such as piperazin-1-yl, 2-methylpiperazin-1-yl, 3-methylpiperazin-1-yl, 4-methylpiperazin-1-yl, 2-ethylpiperazin-1-yl, 3-propylpiperazin-1-yl, 4-isopropylpiperazin-1-yl, 2-butylpiperazin-1-yl, 3-(tert-butyl)piperazin-1-yl or the like;

morpholino;

7-azabicyclo[2.2.1]heptan-7-yl; and

3-azabicyclo[3.2.2]nonan-3-yl or the like, and the most preferred one may include piperidino, 2-methylpiperidino, 2-ethylpiperidino, 3-ethylpiperidino, 4-ethylpiperidino, 2-propylpiperidino, 2,2,6,6-tetramethylpiperidino, 2-hydroxymethylpiperidino, 2-(2-hydroxyethyl)piperidino, 4-(2-hydroxyethyl)piperidino, 2-methoxymethylpiperidino, 2-(2-methoxyethyl)piperidino, 2-acetoxymethylpiperidino, 2-(2-acetoxyethyl)piperidino, 2-ethoxycarbonylpiperidino, 2-carboxypiperidino, 2-(methoxycarbonylmethyl)piperidino, 2-carboxymethylpiperidino, 2-carbamoylmethylpiperidino, 2-(N-ethylcarbamoylmethyl)piperidino, 2-N,N-diethylcarbamoylmethylpiperidino, pyrrolidin-1-yl, 2-methoxymethylpyrrolidin-1-yl, perhydro-1H-azepin-1-yl, 4-methylpiperazin-1-yl, morpholino, 7-azabicyclo[2.2.1]heptan-7-yl, 3-azabicyclo[3.2.2]nonan-3-yl or the like.

[0049] Suitable "aryl" may include phenyl, naphthyl, indenyl, anthryl or the like, and these "aryl" may have one or more suitable substituent(s), such as halogen (e.g. fluoro, chloro, bromo and iodo); lower alkoxy (e.g. methoxy, ethoxy, propoxy, tert-butoxy, pentyloxy, hexyloxy, etc.); nitro; amino; and said protected amino.

[0050] The preferred example of "aryl optionally having one or more suitable substituent(s)" may include phenyl which may have 1 to 3 suitable substituent(s) selected from a group consisting of halogen, (C₁-C₄)alkoxy, nitro, amino, (C₁-C₄)alkanoylamino, (C₁-C₄)alkoxycarbonylamino, (C₁-C₄)alkanasulfonylamino, (C₁-C₄)alkylamino and di(C₁-C₄)alkylamino, in which the more preferred one may be phenyl, phenyl having chloro, phenyl having methoxy, phenyl having nitro, phenyl having amino, phenyl having acetylamino, phenyl having methoxycarbonylamino, phenyl having methanesulfonylamino, phenyl having methylamino, and phenyl having dimethylamino.

[0051] Suitable "heterocyclic group" may include the ones as exemplified for "nitrogen-containing heterocyclic group" as mentioned above;

unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing one oxygen atom, such as furyl or the like;

unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing one oxygen atom and 1 or 2 sulfur atom(s), such as dihydrooxathiinyl or the like;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s), such as benzothienyl, benzodithiinyl or the like;

unsaturated condensed heterocyclic group containing one oxygen atom and 1 or 2 sulfur atom (s), such as benzoxathiinyl or the like, in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), and the more preferred one may be pyridyl, and the most preferred one may be 2-pyridyl, 3-pyridyl and 4-pyridyl.

[0052] Suitable "lower alkenyl having halogen" may include 1-fluorovinyl, 1-bromovinyl, 1-chloro-2-methylvinyl, 1-bromo-1-propenyl, 2-chloro-2-propenyl, 1-iodo-1-butenyl, 1-bromo-2-methyl-1-propenyl, 3-bromo-1,3-butadienyl, 1-chloro-1-pentenyl, 4-chloro-4-pentenyl, 1-bromo-1-hexenyl or the like.

[0053] Suitable "lower alkoxy" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy or the like.

[0054] Suitable "halogen" may include fluoro, chloro, bromo and iodo.

[0055] Suitable "leaving group" may include di(lower)alkylamino, such as dimethylamino, diethylamino, N-ethylpropylamino, dibutylamine, N-pentylhexylamino or the like; lower alkoxy such as mentioned above; halogens mentioned above; and lower alkylthio, such as methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio or the like.

[0056] Suitable "unsaturated heterocyclic group" of said "unsaturated heterocyclic group optionally having one or more suitable substituent(s)" may include unsaturated monocyclic or polycyclic heterocyclic group containing at least one hetero atom, such as nitrogen, oxygen, sulfur or the like.

[0057] Suitable examples of said "unsaturated heterocyclic group" may include unsaturated 3 to 8-membered (preferably 5 to 7-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), such as azepinyl (e.g. 1H-azepinyl, etc.), pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl (e.g. 1,2-dihydropyridyl, 1,4-dihydropyridyl, etc.), tetrahydropyridyl (e.g. 1,2,3,6-tetrahydropyridyl, etc.), pyrimidinyl, dihydropyrimidinyl (e.g. 1,2-dihydropyrimidinyl, etc.), pyrazinyl, pyridazinyl, dihydropyridazinyl (e.g. 2,3-dihydropyridazinyl, 1,4-dihydropyridazinyl, etc.), tetrahydropyridazinyl (e.g. 2,3,4,5-tetrahydropyridazinyl, etc.), triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.) or the like;

- unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), such as indolyl, isoindolyl, indoliz-
 inyl, benzimidazolyl, quinolyl, dihydroquinolyl (e.g. 2,3-dihydroquinolyl, etc.), isoquinolyl, indazolyl, benzotriazolyl or
 the like;
- 5 unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen
 atom(s) and 1 to 3 nitrogen atom(s), such as oxazolyl, isoxazolyl, dihydroisoxazolyl (e.g. 2,5-dihydroisoxazolyl,
 etc.), oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) or the like;
- unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), such as
 benzoxazolyl, benzoxadiazolyl or the like;
- 10 unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur
 atom(s) and 1 to 3 nitrogen atom(s), such as thiazolyl, dihydrothiazolyl (e.g. 2,3-dihydrothiazolyl, etc.), isothiazolyl,
 thiadiazolyl (e.g. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiadinyl or
 the like;
- unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), such as
 benzothiazolyl, benzothiadiazolyl (e.g. benzo[d][1,2,3]thiadiazolyl, etc.), imidazothiadiazolyl (e.g. 5H-imidazo[2,1-
 15 b][1,3,4]thiadiazolyl, etc.) or the like;
- unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur
 atom(s), such as thienyl, dihydrothiynyl or the like;
- unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing one oxygen atom,
 such as furyl or the like;
- 20 unsaturated 3 to 8-membered (preferably 5 or 6-membered) heteromonocyclic group containing one oxygen atom
 and 1 or 2 sulfur atom(s), such as dihydroxathiinyl or the like;
- unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s), such as benzothieryl and benzodithi-
 eryl or the like; and
- 25 unsaturated condensed heterocyclic group containing one oxygen atom and 1 or 2 sulfur atom(s), such as benzox-
 athieryl or the like; and so on.

[0058] Among these, the preferred one may be unsaturated heterocyclic group containing at least one nitrogen
 atom as a hetero atom, and the more preferred one may be unsaturated 3 to 8-membered heteromonocyclic group con-
 taining 1 to 4 nitrogen atom(s) and unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to
 30 3 nitrogen atom(s), and the much more preferred one may be pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyri-
 midinyl, dihydropyrimidinyl, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl and imidazothiadiazolyl, and the most
 preferred one may be pyridazinyl, 2,3-dihydropyridazinyl, 1,4-dihydropyridazinyl, 2,3,4,5-tetrahydropyridazinyl, pyrimid-
 inyl, 1,2-dihydropyrimidinyl, pyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, pyrazolyl and imi-
 dazo[2,1-b][1,3,4]thiadiazolyl.

35 [0059] The "unsaturated heterocyclic group" mentioned above may have one or more (preferably 1 to 4) suitable
 substituent(s), such as lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, etc.) which
 may have one or more (preferably 1 to 4) suitable substituent(s) as mentioned hereinafter; carboxy(lower)alkenyl (e.g.
 1-carboxyvinyl, 2-carboxyvinyl, 1-carboxy-2-propenyl, 3-carboxy-2-propenyl, 3-carboxy-2-butenyl, 4-carboxy-2-methyl-
 2-butenyl, 3-carboxy-1-hexenyl, etc.); amino; di(lower)alkylamino (e.g. dimethylamino, N-methylethylamino, dipro-
 40 pylamino, N-butyl-(2-methylbutyl)amino, N-pentylhexylamino, etc.); halogens (e.g. fluoro, chloro, bromo, iodo, etc.);
 lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, etc.); oxo; hydroxy;
 cyano; acyl group as mentioned below or the like.

[0060] Suitable "acyl group" may include lower alkanoyl group (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl,
 pivaloyl, hexanoyl, etc.), carboxy, protected carboxy or the like.

45 [0061] Suitable example of said "protected carboxy" may be esterified carboxy, the preferred one of which may
 include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, pentyloxy-
 carbonyl, hexyloxycarbonyl, etc.) or the like; and amidated carboxy, the preferred one of which may include carbamoyl
 and N,N-di(lower)alkylcarbamoyl groups, the two lower alkyl groups of which may bond to each other to form a 3 to 6-
 50 membered ring (e.g. N,N-dimethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-diethylcarbamoyl, N,N-dipropylcar-
 bamoyl, N-butyl-N-tert-butylcarbamoyl, N,N-dipentylcarbamoyl, N-pentyl-N-hexylcarbamoyl, 1-aziridinylcarbamoyl, 1-
 azetidinyllcarbamoyl, 1-pyrrolidinylcarbamoyl, piperidinocarbonyl, etc.) or the like.

[0062] Suitable example of the "suitable substituent(s)" of said "lower alkyl which may have one or more suitable
 substituent(s)" may include hydroxy, said halogen, said lower alkoxy, said acyl or the like.

55 [0063] Suitable example of said "lower alkyl group having one or more suitable substituent(s)" may include lower
 alkyl having both hydroxy and halogen, such as 1-hydroxy-1-chloromethyl, 1-hydroxy-2-chloroethyl, 2-hydroxy-3-fluor-
 opropyl, 2-hydroxy-3,3,3-trichloropropyl, 3-bromo-4-hydroxy-4-iodobutyl, 1-chloro-2-hydroxy-4-fluoropentyl, 3,4-dihy-
 droxy-6-chlorohexyl or the like;

hydroxy(lower)alkyl such as hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxy-1-methylethyl, 1-hydroxybutyl, 1-hydroxymethyl-1-methylethyl, 3-hydroxypentyl, 2-hydroxyhexyl or the like;

lower alkoxy(lower)alkyl such as methoxymethyl, ethoxymethyl, 2-ethoxyethyl, 1-propoxyethyl, 3-isopropoxypropyl, 2-butoxybutyl, 1-tert-butoxymethyl-1-methylethyl, 5-pentyloxypropyl, hexyloxymethyl, 3-hexyloxyhexyl or the like; and

acyl(lower)alkyl, the preferred one of which may be carboxy(lower)alkyl (e.g. carboxymethyl, 2-carboxyethyl, 2-carboxypropyl, 3-carboxypropyl, 2-carboxy-1-methylethyl, 4-carboxybutyl, 1-carboxymethyl-1-methylethyl, 3-carboxypentyl, 2-carboxyhexyl, etc.), preferably protected carboxy(lower)alkyl, such as esterified carboxy(lower)alkyl and amidated carboxy(lower)alkyl, still more preferably lower alkoxycarbonyl(lower)alkyl (e.g. methoxycarbonylmethyl, ethoxycarbonylmethyl, 2-methoxycarbonylethyl, 2-ethoxycarbonylethyl, 1-propoxycarbonylethyl, 3-ethoxycarbonylpropyl, 2-butoxycarbonylbutyl, 4-ethoxycarbonylbutyl, 1-tert-butoxycarbonylmethyl-1-methylethyl, 5-pentyloxycarbonylpentyl, hexyloxycarbonylmethyl, 3-hexyloxycarbonylhexyl, etc.), carbamoyl(lower)alkyl (e.g. carbamoylmethyl, 2-carbamoylethyl, 3-carbamoylpropyl, 2-carbamoyl-1-methylethyl, 4-carbamoylbutyl, 1-carbamoylmethyl-1-methylethyl, 5-carbamoylpentyl, 3-carbamoylhexyl, etc.), and N,N-di(lower)alkylcarbamoyl(lower)alkyl in which two lower alkyl groups on nitrogen atom may bond to each other to form 3 to 6-membered ring [e.g. N,N-dimethylcarbamoylmethyl, 2-(N,N-dimethylcarbamoyl)ethyl, 2-(N-methyl-N-ethylcarbamoyl)ethyl, 3-(N-methyl-N-ethylcarbamoyl)propyl, 2-(N,N-dipropylcarbamoyl)-1-methylethyl, 4-(N,N-dipropylcarbamoyl)butyl, 1-(N,N-dimethylcarbamoyl)-methyl-1-methylethyl, 5-(N-pentyl-N-hexylcarbamoyl)pentyl, 3-(N-pentyl-N-hexylcarbamoyl)hexyl, (1-aziridinylcarbonyl)methyl, 2-(1-azetidinyldicarbonyl)ethyl, 2-(piperidinocarbonyl)ethyl, 3-(1-pyrrolidinylcarbonyl)propyl, 2-(piperidinocarbonyl)-1-methylethyl, 4-(1-azetidinyldicarbonyl)butyl, 1-(1-aziridinylcarbonyl)methyl-1-methylethyl, 3-(1-pyrrolidinylcarbonyl)pentyl, 6-(piperidinocarbonyl)hexyl, etc.] or the like.

[0064] The preferred substituent on said "unsaturated heterocyclic group" may be lower alkyl, lower alkyl having hydroxy and halogen, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, carboxy(lower)alkyl, lower alkoxycarbonyl(lower)alkyl, carbamoyl(lower)alkyl, N,N-di(lower)alkylcarbamoyl(lower)alkyl wherein two lower alkyl groups on nitrogen atom may bond to each other to form a 3 to 6-membered ring, carboxy(lower)alkenyl, di(lower)alkylamino, halogen, lower alkoxy, oxo, carboxy, lower alkoxycarbonyl, lower alkanoyl, amino, cyano and hydroxy. Among these, the more preferred one may be (C₁-C₄)alkyl, (C₁-C₄)alkyl having hydroxy and halogen, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkoxy(C₁-C₄)alkyl, carboxy(C₁-C₄)alkyl, (C₁-C₄)alkoxycarbonyl(C₁-C₄)alkyl, carbamoyl(C₁-C₄)alkyl, N,N-di(C₁-C₄)alkylcarbamoyl(C₁-C₄)alkyl, piperidinocarbonyl(C₁-C₄)alkyl, carboxy(C₂-C₄)alkenyl, di(C₁-C₄)alkylamino, halogen, (C₁-C₄)alkoxy, oxo, carboxy, (C₁-C₄)alkoxycarbonyl, (C₁-C₄)alkanoyl, amino, cyano and hydroxy. The most preferred one may be methyl, propyl, 2-hydroxy-3,3,3-trichloropropyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-ethoxyethyl, 2-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, methoxycarbonylmethyl, 2-methoxycarbonylethyl, 3-ethoxycarbonylpropyl, 4-ethoxycarbonylbutyl, 2-carbamoylethyl, 2-(N,N-dimethylcarbamoyl)ethyl, 2-(piperidinocarbonyl)ethyl, 2-carboxyvinyl, dimethylamino, chloro, methoxy, oxo, carboxy, ethoxycarbonyl, methoxycarbonyl, acetyl, amino, cyano and hydroxy.

[0065] The "unsaturated heterocyclic group" of said "unsaturated heterocyclic group which may have one or more suitable substituent(s)" may have one or more (preferably 1 to 4) substituent(s) mentioned below in addition to the ones mentioned hereinbefore.

[0066] The substituent referred to above may include amino(lower)alkyl; lower alkylamino(lower)alkyl; carboxy(lower)alkylamino(lower)alkyl; protected carboxy(lower)alkylamino(lower)alkyl; lower alkylamino(lower)alkyl having hydroxy and aryloxy; protected amino(lower)alkyl; cyano(lower)alkyl; cyano(higher)alkyl; lower alkyl having heterocyclic group in which heterocyclic group may have one or more suitable substituent(s); higher alkyl having heterocyclic group in which heterocyclic group may have one or more suitable substituent(s); ar(lower)alkyl; lower alkenyl; heterocyclic group which may have one or more suitable substituent(s); cyclo(lower)alkyl which may have one or more suitable substituent(s); and cyclo(lower)alkenyl which may have one or more suitable substituent(s).

[0067] These substituents are now explained in the following.

[0068] Suitable "amino(lower)alkyl" may include aminomethyl, 1-aminoethyl, 2-aminoethyl, 2-aminopropyl, 3-aminobutyl, 2-amino-1,1-dimethylethyl, 5-aminopentyl, 1-aminoheptyl, etc. Among these, the preferred one may be amino(C₁-C₄)alkyl, and the more preferred one may be 2-aminoethyl.

[0069] Suitable "lower alkylamino(lower)alkyl" may include mono- or di(lower)alkylamino(lower)alkyl such as methylaminomethyl, 2-(ethylamino)ethyl, 3-(propylamino)propyl, 2-(propylamino)butyl, 2-(t-butylamino)-1,1-dimethylethyl, 4-pentylaminopentyl, 6-hexylaminohexyl, dimethylaminomethyl, 2-dimethylaminoethyl, 1-(N-methylethylamino)ethyl, 1-dimethylaminopropyl, 2-diethylaminopropyl, 3-dimethylaminopropyl, 3-(N-propylbutylamino)butyl, 4-dimethylaminobutyl, 2-dibutylamino-1,1-dimethylethyl, 4-dipentylaminopentyl, 6-(N-pentylhexylamino)hexyl or the like. Among these, preferred one may be di(lower)alkylamino(lower)alkyl, and the more preferred one may be di(C₁-C₄)alkylamino(C₁-C₄)alkyl, and the most preferred one may be 2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl.

[0070] Suitable "carboxy(lower)alkylamino(lower)alkyl" may include carboxymethylaminomethyl, 2-(carboxymethyl-

amino)ethyl, 2-(1-carboxyethylamino)ethyl, 3-(2-carboxypropylamino)propyl, 2-(3-carboxypropylamino)butyl, 2-(2-carboxy-1,1-dimethylethylamino)-1,1-dimethylethyl, 4-(5-carboxypentylamino)pentyl, 6-(3-carboxyhexylamino)hexyl or the like, in which the preferred one may be carboxy(C₁-C₄)alkylamino(C₁-C₄)alkyl, and the most preferred one may be 2-(carboxymethylamino)ethyl.

- 5 [0071] Suitable "protected carboxy" of said "protected carboxy(lower)alkylamino(lower)alkyl" may be esterified carboxy or the like, and concrete example of the ester moiety in said esterified carboxy may include lower alkyl esters (e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.) which may have suitable substituent(s), for example, lower alkanoyloxy(lower)alkyl ester (e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, 1-acetoxyethyl ester, 1-propionyloxyethyl ester, 2-propionyloxyethyl ester, hexanoyloxymethyl ester, etc.), lower alkanesulfonyl(lower)alkyl ester (e.g. 2-mesyloethyl ester etc.) or mono(or di or tri)halo(lower)alkyl ester (e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.); lower alkenyl ester (e.g. vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.); ar(lower)alkyl ester (e.g. benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, etc.) which may have suitable substituent(s); and aryl ester (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, 4-tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.) which may have suitable substituent(s), or the like.

- [0072] Suitable "protected carboxy(lower)alkylamino(lower)alkyl" may include esterified carboxy(lower)alkylamino(lower)alkyl in which the preferred one may be lower alkoxycarbonyl(lower)alkylamino(lower)alkyl, such as methoxycarbonylmethylaminomethyl, 2-(ethoxycarbonylmethylamino)ethyl, 2-(1-ethoxycarbonyl-ethylamino)ethyl, 3-(2-propoxycarbonylpropylamino)propyl, 2-(3-butoxycarbonylpropylamino)butyl, 2-(2-tert-butoxycarbonyl-1,1-dimethylethylamino)-1,1-dimethylethyl, 4-(5-pentyloxycarbonylpentylamino)pentyl, 6-(3-hexyloxycarbonylhexylamino)hexyl or the like. The more preferred one may be (C₁-C₄)alkoxy-carbonyl(C₁-C₄)alkylamino(C₁-C₄)alkyl, and the most preferred one may be 2-(ethoxycarbonylmethylamino)ethyl.

- [0073] Suitable "lower alkylamino(lower)alkyl having hydroxy and aryloxy" may include said "lower alkylamino(lower)alkyl" having "hydroxy" and "aryloxy" (e.g. phenoxy, tolyloxy, naphthylloxy, etc.), the suitable example of which may include 1-(1-naphthylloxy)-1-hydroxymethylaminomethyl, 2-(1-hydroxy-2-phenoxyethylamino)ethyl, 2-[2-hydroxy-3-(1-naphthylloxy)propylamino]ethyl, 2-[4-hydroxy-3-(p-tolyloxy)butylamino]propyl, 2-[4-hydroxy-1-(2-naphthylloxy)butylamino]-1,1-dimethylethyl, 4-[1-hydroxy-5-(1-naphthylloxy)pentylamino]pentyl and 6-[2-hydroxy-4-(2-naphthylloxy)hexylamino]hexyl, in which the preferred one may be (C₁-C₄)alkylamino(C₁-C₄)alkyl having hydroxy and naphthylloxy, and the more preferred one may be 2-[2-hydroxy-3-(1-naphthylloxy)propylamino]ethyl.

[0074] Suitable "protected amino(lower)alkyl" may include acylamino(lower)alkyl.

- [0075] Suitable example of said acylamino may be lower alkanoylamino (e.g. formylamino, acetylamino, propionylamino, hexanoylamino, pivaloylamino, etc.), mono(or di or tri)halo(lower)alkanoylamino (e.g. chloroacetylamino, trifluoroacetylamino, etc.), lower alkoxycarbonylamino (e.g. methoxycarbonylamino, ethoxycarbonylamino, tert-butoxycarbonylamino, tert-pentyloxycarbonylamino, hexyloxycarbonylamino, etc.), mono(or di or tri)-halo(lower)alkoxy-carbonylamino (e.g. chloromethoxycarbonylamino, dichloroethoxycarbonylamino, trichloroethoxycarbonylamino, etc.), aroylamino (e.g. benzoylamino, toluoylamino, xyloylamino, naphthoylamino, etc.), ar(lower)alkanoylamino such as phenyl(lower)alkanoylamino (e.g. phenylacetylaminomethyl, phenylpropionylamino, etc.), aryloxycarbonylamino (e.g. phenoxy-carbonylamino, naphthylloxycarbonylamino, etc.), aryloxy(lower)alkanoylamino such as phenoxy(lower)alkanoylamino (e.g. phenoxyacetylaminomethyl, phenoxypropionylamino, etc.), arylglyoxyloylamino (e.g. phenylglyoxyloylamino, naphthylglyoxyloylamino, etc.), ar(lower)alkoxycarbonylamino which may have suitable substituent(s), such as phenyl(lower)alkoxycarbonylamino which may have nitro or lower alkoxy (e.g. benzyloxycarbonylamino, phenethyloxycarbonylamino, p-nitrobenzyloxycarbonylamino, p-methoxybenzyloxycarbonylamino, etc.), thienylacetylaminomethyl, imidazolylacetylaminomethyl, furylacetylaminomethyl, tetrazolylacetylaminomethyl, thiazolylacetylaminomethyl, thiadiazolylacetylaminomethyl, thienylpropionylaminomethyl, thiadiazolylpropionylaminomethyl, lower alkylsulfonylamino (e.g. methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, pentylsulfonylamino, butylsulfonylamino, etc.), arylsulfonylamino (e.g. phenylsulfonylamino, tolylsulfonylamino, xylylsulfonylamino, naphthylsulfonylamino, etc.), ar(lower)alkylsulfonylamino such as phenyl(lower)alkylsulfonylamino (e.g. benzylsulfonylamino, phenethylsulfonylamino, benzhydrylsulfonylamino, etc.), and imido (e.g. 1,2-cyclohexanedicarboximido, succinimido, phthalimido, etc.) or the like.

- [0076] Preferred example of said "protected amino(lower)alkyl" may be imido(lower)alkyl, such as phthalimidomethyl, 2-phthalimidoethyl, 1-(1,2-cyclohexanedicarboximido)ethyl, 2-succinimidopropyl, 3-phthalimidobutyl, 2-(1,2-cyclohexanedicarboximido)-1,1-dimethylethyl, 5-phthalimidopentyl, 1-phthalimidoethyl or the like. The more preferred one may be imido(C₁-C₄)alkyl, and the most preferred one may be 2-phthalimidoethyl.

- [0077] Suitable "cyano(lower)alkyl" may include cyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 3-cyanopropyl, 2-cyanobutyl, 4-cyanobutyl, 2-cyano-1,1-dimethylethyl, 4-cyanopentyl, 5-cyanopentyl, 6-cyanoethyl or the like, in which the preferred one may be cyano (C₁-C₆)alkyl, and the most preferred one may be cyanomethyl, 2-cyanoethyl, 3-cyan-

opropyl, 4-cyanobutyl, 5-cyanopentyl and 6-cyanoheptyl.

[0078] Suitable "cyano(higher)alkyl" may include 7-cyanoheptyl, 8-cyano-octyl, 4-cyano-octyl, 8-cyano-3-methylheptyl, 9-cyano-nonyl, 1-cyano-nonyl, 10-cyano-decyl, 8-cyano-undecyl, 12-cyano-dodecyl, 11-cyano-4-methylundecyl, 13-cyano-tridecyl, 6-cyano-tetradecyl, 15-cyano-pentadecyl, 12-cyano-hexadecyl, 17-cyano-heptadecyl, 4-cyano-octadecyl, 19-cyano-nonadecyl, 1-cyano-12-ethylheptadecyl, 20-cyano-eicosyl or the like, in which the preferred one may be cyano(C₇-C₁₆)alkyl and the more preferred one may be 7-cyanoheptyl, 8-cyano-octyl, 9-cyano-nonyl, 10-cyano-decyl and 12-cyano-decyl.

[0079] Suitable "lower alkyl" may include straight-chain or branched-chain alkyl such as methyl, ethyl, propyl, isopropyl, butyl, 1-butyl, pentyl, hexyl or the like.

[0080] Suitable "lower alkenyl" may include straight-chain or branched-chain alkenyl such as vinyl, allyl, 2-butenyl, 2-methyl-2-propenyl, 4-pentenyl, 3-hexenyl or the like, in which the preferred one may be (C₂-C₄)alkenyl, and the more preferred one may be vinyl.

[0081] Suitable "lower alkyl" of said "lower alkyl having heterocyclic group, in which heterocyclic group may have one or more suitable substituent(s)" may include the same lower alkyl as mentioned above, and the preferred one may be (C₁-C₆)alkyl, and the most preferred one may be methyl, ethyl, propyl, butyl, pentyl and hexyl.

[0082] Suitable "higher alkyl" of said "higher alkyl having a heterocyclic group, in which heterocyclic group may have one or more suitable substituent(s)" may include heptyl, octyl, 3-methylheptyl, nonyl, 2,6-dimethylheptyl, decyl, undecyl, dodecyl, 4-methyldodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, 12-ethylheptadecyl, eicosyl or the like, in which the preferred one may be (C₇-C₁₆) alkyl, and the more preferred one may be heptyl, octyl, nonyl, decyl and dodecyl.

[0083] Suitable "heterocyclic group" of said "lower alkyl having a heterocyclic group, in which heterocyclic group may have one or more suitable substituent(s)" and of said "higher alkyl having heterocyclic group, in which heterocyclic group may have one or more suitable substituent(s)" may include saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least one hetero atom such as oxygen, sulfur, nitrogen or the like. The particularly preferred heterocyclic group may be 3 to 8-membered unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s), such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g. 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.) or the like;

3 to 8-membered saturated heteromonocyclic group containing 1 to 4 nitrogen atom(s), such as pyrrolidinyl, imidazolidinyl, piperidyl (e.g. piperidino, etc.), piperazinyl or the like;

unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atom(s), such as indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g. tetrazolo[1,5-b]pyridazinyl etc.), dihydrotriazolopyridazinyl or the like;

3 to 8-membered unsaturated heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), such as oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) or the like;

3 to 8-membered saturated heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), such as morpholinyl, oxazolidinyl (e.g. 1,3-oxazolidinyl etc.) or the like;

unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), such as benzoxazolyl, benzoxadiazolyl or the like;

3 to 8-membered unsaturated heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), such as 1,3-thiazolyl, 1,2-thiazolyl, thiazolinyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl) or the like;

3 to 8-membered saturated heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), such as thiazolidinyl or the like;

3 to 8-membered unsaturated heteromonocyclic group containing one sulfur atom, such as thienyl or the like;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), such as benzothiazolyl, benzothiadiazolyl or the like;

3 to 8-membered unsaturated heteromonocyclic group containing 1 or 2 oxygen atom(s), such as furyl, pyranyl, dioxolyl or the like;

3 to 8-membered saturated heteromonocyclic group containing 1 or 2 oxygen atom(s), such as oxolanyl, tetrahydropyranyl (e.g. tetrahydro-2H-pyran-2-yl etc.), dioxolanyl or the like;

unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s), such as isobenzofuranyl, chromenyl (e.g. 2H-chlomen-3-yl etc.), dihydrochromenyl (e.g. 3,4-dihydro-2H-chlomen-4-yl etc.) or the like; and so on.

[0084] Preferred example of said "heterocyclic group" may be 3 to 8-membered unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s); 3 to 8-membered saturated heteromonocyclic group containing 1 to 4 nitrogen

atom(s), 3 to 8-membered saturated heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s); and 3 to 8-membered saturated heteromonocyclic group containing 1 or 2 oxygen atom(s), in which the preferred one may be pyridyl, tetrazolyl, piperidyl, piperazinyl, morpholinyl, oxazolidinyl and tetrahydropyranyl, and the more preferred one may be 4-pyridyl, 1H-tetrazol-5-yl, piperidino, 1-piperazinyl, morpholino, 1,3-oxazolidin-5-yl and tetrahydro-2H-pyran-2-yl.

[0085] The "heterocyclic group" mentioned above may have one or more (preferably 1 to 3) suitable substituent(s) such as hydroxy(lower)alkyl (e.g. hydroxymethyl, 2-hydroxyethyl, 1-hydroxypropyl, 4-hydroxybutyl, 2-hydroxy-1,1-dimethylethyl, 3-hydroxypentyl, 6-hydroxyhexyl, etc.), aryl optionally having lower alkoxy (e.g. phenyl, naphthyl, 2-methoxyphenyl, 2-methoxynaphthyl, 3-ethoxyphenyl, 4-propoxyphenyl, 2-butoxyphenyl, 5-propoxynaphthyl, 3-*t*-butoxyphenyl, 4-pentyloxyphenyl, 2-hexyloxyphenyl, etc.), oxo or the like. The preferred one, among such "suitable substituent(s)", may be hydroxy(C₁-C₄)alkyl, phenyl having (C₁-C₄)alkoxy, and oxo, and the more preferred one may be 2-hydroxyethyl, 2-methoxyphenyl and oxo.

[0086] Suitable "heterocyclic group" of said "heterocyclic group which may have one or more suitable substituent(s)" may include the same groups as mentioned for the "heterocyclic group" of said "lower alkyl having heterocyclic group, in which heterocyclic group may have one or more suitable substituent(s)" and of said "higher alkyl having a heterocyclic group, in which heterocyclic group may have one or more suitable substituent(s)", and the preferred one may be unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and the more preferred one may be dihydrochromenyl, and the most preferred one may be 3,4-dihydro-2H-chromen-4-yl.

[0087] This "heterocyclic group" may have one or more (preferably 1 to 4) suitable substituent(s) such as said lower alkyl, hydroxy, cyano or the like, in which the preferred one may be (C₁-C₄)alkyl, hydroxy and cyano, and the most preferred one may be methyl, hydroxy and cyano.

[0088] Suitable "ar(lower)alkyl" may include mono- or di- or tri-phenyl(lower)alkyl (e.g. benzyl, phenethyl, 2-phenylpropyl, 4-phenylbutyl, 2-phenyl-1,1-dimethylethyl, 1-phenylpentyl, 6-phenylhexyl, benzhydryl, trityl, etc.) or the like, in which the preferred one may be phenyl(C₁-C₄)alkyl, and the most preferred one may be benzyl.

[0089] Suitable "nitrogen-containing heterocyclic group" of said "nitrogen-containing heterocyclic group which may have one or more suitable substituent(s)" may include heterocyclic group containing at least one nitrogen atom as its ring member among said "heterocyclic group", and this "nitrogen-containing heterocyclic group" may have one or more (preferably 1 to 3) suitable substituent(s) (e.g. said hydroxy(lower)alkyl, said aryl which may have lower alkoxy, oxo, etc.).

[0090] Suitable "tetrazolyl(lower)alkyl" may include 1H-tetrazol-5-ylmethyl, 2-(1H-tetrazol-5-yl)ethyl, 3-(1H-tetrazol-5-yl)propyl, 4-(1H-tetrazol-5-yl)butyl, 2-(2H-tetrazol-2-yl)-1,1-dimethylethyl, 4-(1H-tetrazol-1-yl)pentyl, 5-(1H-tetrazol-5-yl)pentyl, 6-(1H-tetrazol-5-yl)hexyl or the like, in which the preferred one may be tetrazolyl(C₁-C₆)alkyl, and the more preferred one may be (1H-tetrazol-5-yl)methyl, 2-(1H-tetrazol-5-yl)ethyl, 3-(1H-tetrazol-5-yl)propyl, 4-(1H-tetrazol-5-yl)butyl, 5-(1H-tetrazol-5-yl)pentyl, and 6-(1H-tetrazol-5-yl)hexyl.

[0091] Suitable "tetrazolyl(higher)alkyl" may include 7-(1H-tetrazol-5-yl)heptyl, 8-(1H-tetrazol-5-yl)octyl, 4-(1H-tetrazol-1-yl)octyl, 8-(1H-tetrazol-5-yl)-3-methylheptyl, 9-(1H-tetrazol-5-yl)nonyl, 1-(1H-tetrazol-1-yl)nonyl, 10-(1H-tetrazol-5-yl)decyl, 8-(1H-tetrazol-5-yl)undecyl, 12-(1H-tetrazol-5-yl)dodecyl, 11-(1H-tetrazol-5-yl)-4-methylundecyl, 13-(1H-tetrazol-5-yl)tridecyl, 6-(1H-tetrazol-5-yl)-tetradecyl, 15-(1H-tetrazol-5-yl)-pentadecyl, 12-(1H-tetrazol-5-yl)-hexadecyl, 17-(1H-tetrazol-1-yl)-heptadecyl, 4-(1H-tetrazol-5-yl)-octadecyl, 19-(1H-tetrazol-5-yl)-nonadecyl, 1-(1H-tetrazol-1-yl)-12-ethylheptadecyl, 20-(1H-tetrazol-5-yl)icosyl or the like, in which the preferred one may be tetrazolyl(C₇-C₁₆)alkyl, and the more preferred one may be 7-(1H-tetrazol-5-yl)heptyl, 8-(1H-tetrazol-5-yl)octyl, 9-(1H-tetrazol-5-yl)nonyl, 10-(1H-tetrazol-5-yl)decyl and 12-(1H-tetrazol-5-yl)dodecyl.

[0092] Suitable "cyclo(lower)alkyl" may include cyclo(C₃-C₈)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclo(C₅-C₇)alkyl such as cyclopentyl, cyclohexyl, cycloheptyl or the like.

[0093] The "cyclo(lower)alkyl" mentioned above may have one or more (preferably 1 to 3) suitable substituent(s) selected from among acyl(lower)alkyl, acyl(lower)alkylidene or the like.

[0094] Suitable "cyclo(lower)alkenyl" may include cyclo(C₃-C₈)alkenyl such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl or the like, in which the preferred one may be cyclo(C₅-C₇)alkenyl such as cyclopentenyl, cyclohexenyl, cycloheptenyl or the like, and the more preferred one may be cyclohexenyl or cycloheptenyl.

[0095] The "cyclo(lower)alkenyl" mentioned above may also have one or more (preferably 1 to 3) suitable substituents such as those mentioned above for "cyclo(lower)alkyl".

[0096] Suitable example of the above "acyl(lower)alkyl" may include carboxy(lower)alkyl (e.g. carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, 1-carboxymethylethyl, 4-carboxybutyl, 2-carboxymethyl-2-methylethyl, 5-carboxypentyl, 3-carboxyhexyl, etc.) and lower alkanoyl(lower)alkyl (e.g. acetylmethyl, formylmethyl, 2-acetylethyl, 2-propionylpropyl, 4-butyrylbutyl, 3-pentanoylpentyl, 6-hexanoylhexyl, etc.), in which the preferred one may be carboxy (C₁-C₄) alkyl or (C₁-C₄)alkanoyl(C₁-C₄)alkyl, and the more preferred one may be carboxymethyl, 2-carboxyethyl, 3-carboxypropyl or acetyl.

methyl.

[0097] Other preferred example of "acyl(lower)alkyl", may include protected carboxy(lower)alkyl, in which the preferred one may be esterified carboxy(lower)alkyl, and the more preferred one may be lower alkoxy carbonyl(lower)alkyl (e.g. methoxycarbonylmethyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, 1-propoxycarbonylpropyl, 2-isopropoxycarbonylpropyl, butoxycarbonylmethyl, t-butoxycarbonylmethyl, 4-isobutoxycarbonylbutyl, 3-pentyloxycarbonylpentyl, 6-hexyloxycarbonylhexyl, (1-cyclopropylethoxycarbonyl)methyl, etc.) and phenyl(lower)alkoxy carbonyl(lower)alkyl (e.g. benzyloxycarbonylmethyl, 2-benzyloxycarbonylethyl, 1-phenethyloxycarbonylethyl, 3-benzyloxycarbonylpropyl, 2-benzyloxycarbonylbutyl, 2-phenethyloxycarbonylmethyl-2-methylethyl, 3-benzyloxycarbonylpentyl, 6-benzyloxycarbonylhexyl, etc.), and the more preferred one may be (C₁-C₄)alkoxy carbonyl(C₁-C₄)alkyl or phenyl(C₁-C₄)alkoxy carbonyl(C₁-C₄)alkyl, and the particularly preferred one may be methoxycarbonylmethyl, ethoxycarbonylmethyl, t-butoxycarbonylmethyl, 2-benzyloxycarbonylethyl and 3-benzyloxycarbonylpropyl.


[0098] Suitable example of "acyl(lower)alkylidene" may include carboxy(lower)alkylidene (e.g. carboxymethylene, 2-carboxyethylidene, 2-carboxypropylidene, 4-carboxybutylidene, 5-carboxypentylidene, 3-carboxyhexylidene, etc.), in which the preferred one may be carboxy(C₁-C₄)alkylidene, and the more preferred one may be carboxymethylene.

[0099] Other suitable example of "acyl(lower)alkylidene" may include protected carboxy(lower)alkylidene, in which the preferred one may be esterified carboxy(lower)alkylidene, and the more preferred one may be lower alkoxy carbonyl(lower)alkylidene such as methoxycarbonylmethylene, ethoxycarbonylmethylene, 2-ethoxycarbonylethylidene, 1-propoxycarbonylpropylidene, 2-isopropoxycarbonylpropylidene, butoxycarbonylmethylene, t-butoxycarbonylmethylene, 4-isobutoxycarbonylbutylidene, 3-pentyloxycarbonylpentylidene, 6-hexyloxycarbonylhexylidene, (1-cyclopropylethoxycarbonyl)methylene or the like. The further more preferred one may be (C₁-C₄)alkoxy carbonyl(C₁-C₄)alkylidene, and the particularly preferred one may be methoxycarbonylmethylene, ethoxycarbonylmethylene and t-butoxycarbonylmethylene.


[0100] Among the pyrazolopyridine compound (I) described above, the particularly preferred compound for practicing the present invention may include the following ones.

- (1) (2R)-1-[3-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(2-hydroxyethyl)piperidine (transisomer)
- (2) 3-[2-(3-Carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine
- (3) (2R)-1-[3-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(carboxymethyl)piperidine (transisomer)
- (4) 3-[2-(2-Carboxymethyl-1-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine

[0101] As other specific examples of the adenosine A₁ antagonist, xanthine compounds of the following general formula (II) and salts thereof can be mentioned.



[wherein R⁷, R⁸, and R¹⁰ each independently is hydrogen, a lower aliphatic hydrocarbon group which may have one or more suitable substituent(s), higher alkyl which may have one or more suitable substituent(s), or ar(lower)alkyl which may have one or more suitable substituent(s), R⁹ is hydrogen; alicyclic group, aryl, heterocyclic group, alicycl(yl)(lower)alkyl, ar(lower)alkyl or a heterocyclic(lower)alkyl, each of which may have one or more substituent(s); or a group of the formula:



5

10 (wherein R^{11} and R^{12} each independently is alicyclic group which may have one or more suitable substituent(s) or aryl which may have one or more suitable substituent(s),
 A^1 is lower alkylene, and
 n is 0 or 1), and

15 X^1 and X^2 each independently is an oxygen atom or a sulfur atom} (exclusive of caffeine and pentoxiphylline).

[0102] Suitable salt of the above xanthine compound may include salts of the kinds mentioned hereinbefore with reference to pyrazolopyridine compound (I).

20 [0103] The xanthine compound (II) includes all the compounds described in EP 0386675, EP 0415456, Japanese laid-open H2-247180, and WO 90/12797. Therefore, the respective groups of compound (II) include all the corresponding groups of the compounds described in the above literature.

[0104] The following definitions pertain to particularly preferred examples of the compound (II).

25 [0105] Suitable "lower aliphatic hydrocarbon group" of said "lower aliphatic hydrocarbon group which may have one or more suitable substituent(s)" may include the same lower alkyl, lower alkenyl and lower alkynyl as mentioned for the pyrazolopyridine compound (I).

[0106] The above "lower aliphatic hydrocarbon group" may have one or more (preferably 1 to 3) suitable substituent(s), such as, for example, hydroxy, amino, the halogen mentioned for compound (I), and the aryl mentioned for compound (I).

30 [0107] The preferred example of the above "lower aliphatic hydrocarbon group" may be (C_1-C_4) alkyl, (C_2-C_4) alkenyl and (C_2-C_4) alkynyl, and the more preferred one may be (C_1-C_4) alkyl, and the most preferred one may be propyl.

[0108] Suitable "higher alkyl" of "higher alkyl which may have one or more suitable substituent(s)" may include the same groups as mentioned for compound (I), and this "higher alkyl" may have one or more (preferably 1 to 3) suitable substituent(s) such as those mentioned hereinabove for "lower aliphatic hydrocarbon group".

[0109] Suitable "ar(lower)alkyl" may include the same groups as mentioned for compound (I).

35 [0110] This "ar(lower)alkyl" may have one or more (preferably 1 to 3) suitable substituent(s) such as said lower alkyl, said halogen, hydroxy, and said lower alkoxy or the like.

40 [0111] Suitable "alicyclic group" and suitable "alicyclic moiety" of said "alicyclic(lower)alkyl" may include cyclo(C_3-C_8)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl [particularly preferred one may be cyclo(C_3-C_6)alkyl]; (C_7-C_{12}) bicycloalkyl or (C_7-C_{12}) bicycloalkenyl groups [particularly preferred one may be groups of the formula




45

50


(wherein ----- represents a single bond or a double bond), groups of the formula:

55



etc.];

(C₇-C₁₂)tricycloalkyl (particularly preferred one may be groups of the formula:



(wherein m is 0 or 1)), or the like.

[0112] Suitable "heterocyclic group" and suitable "heterocyclic moiety" of said "heterocyclic(lower)alkyl" may include the same groups as mentioned for the "heterocyclic group" in the description of the compound (I).

[0113] Suitable "aryl" may include the same groups as mentioned for compound (I).

[0114] The preferred "lower alkyl" of said "alicyclic(lower)alkyl" and of said "heterocyclic(lower)alkyl" may include the same groups as mentioned above for "lower alkyl".

[0115] The alicyclic group, aryl, heterocyclic group, alicyclic(lower)alkyl, ar(lower)alkyl and heterocyclic(lower)alkyl for R⁹ may each have one or more (preferably 1 to 3) suitable substituent(s), such as oxo, hydroxy, amino, said lower alkyl, carboxy, and the protected carboxy mentioned for compound (I) hereinbefore.


[0116] The "alicyclic group" and "aryl" mentioned for R¹¹ and R¹² may each have one or more (preferably 1 to 3) suitable substituent(s), such as said lower alkyl, hydroxy, the lower alkoxy mentioned for compound (I), said halogen, amino, nitro or the like.

[0117] Suitable "lower alkylene" may include methylene, ethylene, 1-methylethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene or the like, and the preferred one may be (C₁-C₄)alkylene.

[0118] The preferred example of the xanthine compound (II) may be as follows.


[0119] R⁷ and R⁸ each is preferably lower alkyl, more preferably (C₁-C₄)alkyl, and most preferably propyl.

[0120] The preferred R⁹ may include cyclo(C₃-C₈)alkyl which may have oxo; (C₇-C₁₂)tricycloalkyl; and groups of the formula:




(wherein R¹¹ and R¹² each is cyclo(C₃-C₈)alkyl).


[0121] The more preferred one may be cyclo(C₃-C₈)alkyl which may have oxo; groups of the formula:




(wherein m is as defined above); and groups of the formula:



(wherein R¹¹ and R¹² each is cyclo(C₃-C₆)alkyl);
and the most preferred one may be cyclopentyl having oxo; groups of the formula:



and groups of the formula:



(wherein R¹¹ and R¹² each is cyclopropyl).

[0122] Preferably, R¹⁰ is hydrogen.

[0123] Preferably, X¹ and X² each is an oxygen atom.

[0124] Among the xanthine compound (II) described above, the particularly preferred compound for the practice of the present invention may include the following ones.

- (1) 8-(Noradamantan-3-yl)-1,3-dipropylxanthine
- (2) 8-Cyclopentyl-1,3-dipropylxanthine

[0125] The pharmaceutical composition suited for the practice of the present invention may be the bulk of adenosine A₁ antagonist or a salt thereof, or in the form of a solid, semisolid or liquid pharmaceutical preparation containing said antagonist or salt thereof as an active ingredient together with an organic or inorganic carrier or excipient suitable for rectal administration, oral or parenteral (inclusive of subcutaneous, intravenous and intramuscular) administration, intratesticular administration, intraurethral administration, intradeferral administration, intrascrotal administration, administration into the female reproductive organ (e.g. intravaginal administration, intrauterine administration, etc.), administration to the ejaculated seminal fluid in various artificial insemination procedures, administration to sperm in the presence of ova *in vitro* fertilization, or inhalation. The active ingredient can be compounded with the conventional non-toxic, pharmaceutically acceptable carriers for use in the preparation of tablets, pellets, troches, capsules, supposito-

ries, aerosols, powders for inhalation, solutions, emulsions, suspensions and any other form suitable for use. Where necessary, adjuvants (auxiliary agents), stabilizers, thickeners, coloring agents and perfumes can be used. The adenosine A₁ antagonist or its salt can be contained in the pharmaceutical preparation at a sufficient level to produce an expected therapeutic effect according to the course or status of disease.

5 [0126] The pharmaceutical preparations for use in the practice of the present invention can be manufactured by the procedures established in the art. Where necessary, the techniques used in the art for enhancing the bioavailability of drugs can also be applied to the manufacture of the pharmaceutical preparations of the invention.

[0127] When a preparation of the invention is applied in an infertile man, it is preferably administered by the intravenous (inclusive of addition to an infusion), intramuscular, oral, intratesticular, intraurethral, intradeferehtal or intracrotal route, or into the female reproductive organ, or to ejaculated seminal fluids in various artificial insemination procedures or to sperm in the presence of ova in vitro fertilization.

[0128] The therapeutically effective dose of the adenosine A₁ antagonist varies with the patient's age and other factors, but for the treatment of male sterility, 0.01–200 mg, as the adenosine A₁ antagonist, per kilogram body weight can be administered daily.

15 [0129] The preparation may also be administered for the prophylaxis of male sterility. Furthermore, it is also expected to find application in female infertility as well as in male sterility. In addition, its utilization as an in vitro diagnostic reagent for sperm function testing is also expected.

Claims


20

1. A therapeutic composition for male sterility which comprises an adenosine A₁ antagonist or a salt thereof as an active ingredient.

25

2. A therapeutic composition of claim 1, wherein the adenosine A₁ antagonist is a pyrazolopyridine compound of the following general formula or a salt thereof:

30




35

[wherein R¹ is lower alkyl, aryl which may have one or more suitable substituent(s) or a heterocyclic group;

40

R² is a group of the formula:

45



50

(wherein R⁴ is protected amino or hydroxy, and R⁵ is hydrogen or lower alkyl);

cyano;

group of the formula:

55



(wherein R⁶ is acyl group, and A is lower aliphatic hydrocarbon group which may have one or more suitable

substituent(s));

amidated carboxyl;


unsaturated heterocyclic group which may have one or more suitable substituent(s);

amino; or

protected amino; and

R³ is hydrogen, lower alkyl, lower alkoxy, or halogen].

3. A therapeutic composition of claim 2, wherein the adenosine A₁ antagonist is a pyrazolopyridine compound of the formula:



(wherein R¹ is aryl,


R is acyl(lower)alkyl or hydroxy(lower)alkyl, and

A is lower alkenyl).

4. A therapeutic composition of claim 3, wherein the adenosine A₁ antagonist is a compound as defined in claim 3 in which R¹ is phenyl, and R is carboxy(lower)alkyl.

5. A therapeutic composition of claim 4, wherein the adenosine A₁ antagonist is 1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(carboxymethyl)piperidine.

6. A therapeutic composition of claim 2, wherein the adenosine A₁ antagonist is a pyrazolopyridine compound of the formula:



[wherein R₁ is aryl, and

R² is dihydropyridazinyl having acyl(lower)alkyl and oxo;

dihydropyridazinyl having cyclo(lower)alkyl substituted by acyl(lower)alkyl or acyl(lower)alkylidene and oxo; or


dihydropyridazinyl having cyclo(lower)alkenyl substituted by acyl(lower)alkyl or acyl(lower)alkylidene and oxo].

7. A therapeutic composition of claim 6, wherein the adenosine A₁ antagonist is a compound as defined in claim 6 in which


R¹ is phenyl and

R^2 is a 3-oxo-2,3-dihydropyridazinyl having carboxy(lower)alkyl or 3-oxo-2,3-dihydropyridazinyl having cyclo(lower)alkenyl substituted by carboxy(lower)alkyl.

8. A therapeutic composition of claim 7, wherein the adenosine A_1 antagonist is 3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine.
9. A therapeutic composition of claim 7, wherein the adenosine A_1 antagonist is 3-[2-(2-carboxymethyl-1-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine.
10. A therapeutic composition of claim 1, wherein the adenosine A_1 antagonist is a xanthine compound of the following formula (exclusive of caffeine and pentoxiphylline) or a salt thereof.



(wherein R^7 , R^8 and R^{10} each independently is hydrogen, lower aliphatic hydrocarbon group which may have one or more suitable substituent(s), higher alkyl which may have one or more suitable substituent(s), or ar(lower)alkyl which may have one or more suitable substituent(s), R^9 is hydrogen; alicyclic group, aryl, heterocyclic group, alicyclic(lower)alkyl, ar(lower)alkyl or heterocyclic(lower)alkyl, each of which may have one or more suitable substituent(s); or a group of the formula:




(wherein R^{11} and R^{12} each is alicyclic group which may have one or more suitable substituent(s) or aryl which may have one or more suitable substituent(s), A^1 is a lower alkylene, and n is 0 or 1), and

X^1 and X^2 each is an oxygen atom or a sulfur atom].

11. A therapeutic composition of claim 10, wherein the adenosine A_1 antagonist is a compound as defined in claim 10 in which

R^7 and R^8 each is lower alkyl,

R^9 is cyclo(C_3 - C_6)alkyl which may have oxo; (C_7 - C_{12})tricycloalkyl; or a group of the formula:



(where R¹¹ and R¹² each is cyclo(C₃-C₈)alkyl)

R¹⁰ is hydrogen, and

X¹ and X² each is an oxygen atom.

12. A therapeutic composition of claim 1, wherein the adenosine A₁ antagonist is a specific adenosine A₁ antagonist.
13. A therapeutic composition of claim 1, wherein the adenosine A₁ antagonist is a substance having adenosine A₁ antagonist activity with an IC₅₀ value of not more than 100 μM.
14. A therapeutic composition of claim 1, wherein the adenosine A₁ antagonist is a substance having adenosine A₁ antagonist activity with an IC₅₀ value of not more than 50 μM.
15. A therapeutic composition of claim 1, wherein the adenosine A₁ antagonist is a substance having adenosine A₁ antagonist activity with an IC₅₀ value of not more than 10 μM.
16. A therapeutic composition of claim 1, wherein the adenosine A₁ antagonist is a substance having adenosine A₁ antagonist activity with an IC₅₀ value of not more than 1 μM.
17. Use of an adenosine A₁ antagonist for the production of a therapeutic composition for male sterility.
18. A method for therapy of male sterility which comprises administering an adenosine A₁ antagonist to a patient with male sterility.
19. A promoter for an induction of sperm acrosomal reaction comprising an adenosine A₁ antagonist or a salt thereof as an active ingredient.
20. Use of an adenosine A₁ antagonist for the production of a promoter for an induction of sperm acrosomal reaction.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/02811

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁴ A61K45/00, A61K31/435, A61K31/52, C07D471/04, C07D473/04 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁴ A61K45/00, A61K31/435, A61K31/52, C07D471/04, C07D473/04 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), REG (STN), MEDLINE (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TAKAHASHI, Y. et al., "In vivo fertilization of bovine oocytes in the presence of thophylline" Animal Reproduction Science, 1993, Vol. 34, p.1-18, (Refer to the full text)	1, 10, 12-17, 19, 20
Y	LINDEN, J., and DELAHUNTY, T.M., "Receptors that inhibit phosphoinositide breakdown" Trends Pharmacol. Sci., 1989, Vol. 10, No. 3, p.114-120, (Refer to p.115-117 "Adenosine")	1-17, 19, 20
Y	ANAND, S.R., et al., "In vitro capacitation of goat spermatozoa" Ind. J. Exp. Biol., 1989, Vol. 27, p.921-924, (Refer to the full text)	1-17, 19, 20
Y	HYNE, R.V., et al., "Calcium-dependent increase in adenosine 3'5'-monophosphatase and induction of the acrosome reaction in guinea pig spermatozoa" Proc. Natl. Acad. Sci. USA, 1979, Vol. 76, No. 11, p.5699-5703	1-17, 19, 20
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search 24 August, 1999 (24. 08. 99)		Date of mailing of the international search report 31 August, 1999 (31. 08. 99)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/02811

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP, 467248, A2 (FUJISAWA PHARMACEUTICAL CO., LTD.), 22 January, 1992 (22. 01. 92), Refer to Claims ; Examples & JP, 4-253978, A & US, 5204346, A	1, 2, 6-9, 12-17, 19, 20
Y	EP, 516941, A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 9 December, 1992 (09. 12. 92), Refer to the full text & JP, 5-112566, A & US, 5234930, A	1-5, 12-17, 19, 20
Y	EP, 379979, A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 1 August, 1990 (01. 08. 90), Refer to Examples 35, 36 & JP, 2-243689, A & US, 4985444, A	1, 2, 6-9, 12-17, 19, 20
Y	WO, 95/18128, A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 6 July, 1995 (06. 07. 95), Refer to page 1, line 30 to page 4, line 24 & JP, 9-507485, A & EP, 737193, A1 & US, 5773530, A	1, 2, 6-9, 12-17, 19, 20
Y	EP, 374808, A2 (BOEHRINGER INGELHEIM KG), 27 June, 1990 (27. 06. 90), Refer to page 2, line 1 to page 5, line 51 ; page 6, "Tabelle 1a" & JP, 2-247180, A & US, 5532368, A	1, 10-17, 19, 20
Y	EP, 415456, A2 (KYOWA HAKKO KOGYO CO., LTD.), 6 March, 1991 (06. 03. 91), Refer to pages 9 to 12, "Table 1" ; pages 13, 14, "Test Example 2" ; page 15, "Table 2" & JP, 3-173889, A & US, 5525607, A	1, 10-17, 19, 20

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/02811

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 18 pertains to methods for prevention or treatment of the human body and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCR and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remarks on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.